tyrphostin-ag825 and Adenocarcinoma

tyrphostin-ag825 has been researched along with Adenocarcinoma* in 1 studies

Other Studies

1 other study(ies) available for tyrphostin-ag825 and Adenocarcinoma

ArticleYear
Tyrphostins and retinoids cooperate during inhibition of in vitro growth of ovarian cancer cells.
    Cancer letters, 2003, Jan-28, Volume: 189, Issue:2

    Chemoresistance of ovarian cancer can be overcome by co-administration of retinoids, albeit clinical proof of this hypothesis is pending. Moreover, growth factor/c-erbB signaling is crucial for ovarian tumor growth/chemosensitivity. Retinoids and c-erbB modulators therefore represent promising drugs for ovarian cancer. We demonstrate that c-erbB-1 (RG-14620, AG1517) and c-erbB-2 selective tyrphostins (AG825, AG879), and all-trans and 9-cis retinoic acid inhibit ovarian cancer cell proliferation (HOC-7, OVCAR-3). Unlike retinoids, AG1517 and AG879 induce apoptosis. The antiproliferative activity of AG1517 is enhanced by all-trans retinoic acid suggesting that c-erbB and retinoid pathways interact. Thus, these agents cooperate during ovarian cancer cell growth inhibition.

    Topics: Adenocarcinoma; Apoptosis; Benzothiazoles; Cell Division; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Humans; Neoplasm Proteins; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; Tretinoin; Tumor Cells, Cultured; Tyrphostins

2003